Ascendis to Share New Rare Disease Endocrinology Data
Ascendis is set to present 52-week pivotal data linking improvements in lower extremity alignment to gains in physical functioning...
eClinical Tech News
Rezolute Aligns With FDA on Streamlined Ersodetug Trial
Rezolute secured FDA alignment to convert its ongoing upLIFT study of ersodetug in tumor-associated hyperinsulinism into a single‑arm, open‑label...
Jade Biosciences Doses First Cohort in JADE101 Phase 1 Trial
Jade Biosciences has begun dosing in a randomized, double-blind, placebo-controlled Phase 1 study of JADE101, a subcutaneous, fully human...
New Vascepa Data Shows Reduced CVD Risk, Hospitalizations
Among REDUCE-IT participants with cardiovascular-kidney-metabolic (CKM) syndrome and baseline eGFR below 60 mL/min/1.73m2, icosapent ethyl cut time to first...
Cytokinetics Reveals New MAPLE-HCM Data at ESC Congress 2025
Aficamten improved peak oxygen uptake by a mean of 1.1 mL/kg/min at 24 weeks, while metoprolol declined by 1.2...
Interim Data for Pediatric HCM from Tenaya’s MyCLIMB Study
Interim data from Tenaya’s MyClimb natural history study of MYBPC3-associated pediatric HCM reported a 93% prevalence of nonobstructive disease...
Cancer Drug Destiny: Bicycle Toxin Conjugate Trial Report
No quantitative efficacy data were disclosed; however, a new industry report highlights early Phase 1/2 signals for bicycle toxin...
RNA Polymerase I Clinical Trials: A Promising 2025 Report
No approved RNA Polymerase I inhibitors are on the market, but the lead asset, pindnarulex (CX-5461), has advanced into...
Celcuity to Submit Gedatolisib NDA in PIK3CA Wild-Type Cohort Under FDA’s RTOR Program
Gedatolisib delivered a hazard ratio of 0.24 for progression-free survival in the PIK3CA wild-type cohort of the Phase 3...
BXCL’s At-Home Igalmi Trial Meets Primary Endpoint
In the Phase 3 SERENITY At-Home trial, BXCL501 120 mcg met its primary endpoint of tolerability for self-administered treatment...